Skip to Main Content

Advertisement

Skip Nav Destination

Abstract 2641: The development of potent, selective RET inhibitors that target both wild-type RET and prospectively identified resistance mutations to multi-kinase inhibitors

Cancer Res (2016) 76 (14_Supplement): 2641.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
  • Carla COLOMBO
  • Noemi GIANCOLA
  • Laura FUGAZZOLA
Minerva Endocrinology (2021) 46 (1)
  • Steven P. Weitzman
  • Steven I. Sherman
Endocrinology and Metabolism Clinics of North America (2019) 48 (1): 253.
  • Sara Redaelli
  • Ivan Plaza-Menacho
  • Luca Mologni
Endocrine-Related Cancer (2018) 25 (2): T53.
  • Julien Hadoux
  • Martin Schlumberger
Best Practice & Research Clinical Endocrinology & Metabolism (2017) 31 (3): 335.
Close Modal

or Create an Account

Close Modal
Close Modal